Atara Biotherapeutics (NASDAQ:ATRA) Trading Down 6%

Atara Biotherapeutics Inc (NASDAQ:ATRA) shares traded down 6% during mid-day trading on Friday . The company traded as low as $15.03 and last traded at $15.03, 614,327 shares were traded during trading. A decline of 21% from the average session volume of 772,985 shares. The stock had previously closed at $15.99.

A number of analysts have recently issued reports on the stock. BidaskClub upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. Stifel Nicolaus reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, October 25th. JPMorgan Chase & Co. downgraded Atara Biotherapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $43.00 to $22.00 in a research note on Friday, November 8th. Zacks Investment Research downgraded Atara Biotherapeutics from a “buy” rating to a “sell” rating in a research note on Friday, January 10th. Finally, Goldman Sachs Group downgraded Atara Biotherapeutics from a “neutral” rating to a “sell” rating and reduced their target price for the stock from $14.00 to $9.00 in a research note on Friday, September 27th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. Atara Biotherapeutics presently has a consensus rating of “Buy” and a consensus target price of $28.22.

The company has a 50 day moving average of $15.64 and a 200-day moving average of $14.59. The firm has a market capitalization of $865.87 million, a P/E ratio of -2.85 and a beta of 2.07. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.05.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.40) by $0.09. As a group, sell-side analysts forecast that Atara Biotherapeutics Inc will post -5.45 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Atara Biotherapeutics by 59.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,699 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,010 shares during the period. Tower Research Capital LLC TRC bought a new stake in shares of Atara Biotherapeutics in the 3rd quarter valued at about $40,000. Bank of Montreal Can grew its position in shares of Atara Biotherapeutics by 81.1% in the 2nd quarter. Bank of Montreal Can now owns 8,314 shares of the biotechnology company’s stock valued at $167,000 after buying an additional 3,723 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in shares of Atara Biotherapeutics by 25.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 12,682 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 2,550 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY grew its position in shares of Atara Biotherapeutics by 17.3% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 15,648 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 2,307 shares during the last quarter.

About Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Article: Coverage Ratio

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.